Abstract
Objective To investigate the diagnostic and prognostic role of gastric fluid DNA (gfDNA) in gasric cancer (GC) patients and controls submitted to upper digestive endoscopy.
Design The concentration of gfDNA was evaluated in 941 samples, including subjects with normal gastric mucosa (n = 10), peptic diseases (n = 596), pre-neoplastic conditions (n = 99), and cancer (n = 236). gfDNA levels were evaluated according to age, gender, BMI, gastric fluid’s pH, use of proton-pump inhibitors, GC tumor subtypes, histological grades, clinical stages, and disease progression/outcome.
Results In the non-cancer group, we observed that gfDNA levels are increased in women as compared to men (p=7.44e-4). Remarkably, gfDNA levels are increased in GC patients as compared to non-GC (normal + peptic diseases, p=5.67e-13) and in GC versus pre-neoplastic disease (p=1.53e-6). Similar differences were also seen when more advanced tumors (T3) were compared to early stages (T2 and below) (p=5.97-4). Moreover, our results suggest the prognostic value of gfDNA as GC-patients with higher gfDNA concentrations (<1.28ng/µl) had increased infiltration of immune cells in the tumor (p=1.06e-3), which parallels with better disease-free survival (p= 0.014).
Conclusion These findings highlight the significance of collecting and studying stomach fluids from gastric cancer patients and reveals the potential impact of this approach as well as its diagnostic and prognostic value for disease management.
What is already known on this topic
- The DNA contained in biofluids that are in direct contact with tumor lesions is a valuable source of information for cancer diagnosis treatment.
- Gastric fluids are in direct contact with gastric cancer (GC) lesions and immune cell infiltrates and may be a reliable source of biomarkers with multiple applications.
- Liquid biopsies are usually based on the detection and analysis of cell-free DNA found in the plasma, urine or saliva.
- Studies of the DNA present in the gastric fluids of patients (gfDNA), collected during routine endoscopy, are scarce and limited to assessing mutation profiles. It’s diagnostic and prognostic potential has not been studied so far.
What this study adds
- An analysis of gfDNA concentrations in 941 samples revealed increased DNA levels in GC patients as compared to non-GC individuals.
- When tumor stages were compared, gfDNA levels are elevated in more advanced disease.
- For GC subjects, increased gfDNA was positively associated with immune cell infiltrates and reduced tumor recurrence, suggesting this to be an informative and very low-cost prognostic marker.
How this study might affect research, practice or policy
- gfDNA collected during routine upper digestive diagnostic endoscopy can be used as an additional and very simple biomarker useful during patient follow-up and to determine cancer prognosis.
- In the future gfDNA assessment has the potential to contribute to a range of applications, such as monitoring treatment response, indicating immune cell infiltration and may potentially indicate cases with progressive disease non-responsive to chemotherapy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The collection of samples and metadata, DNA extraction and further analyses performed here were supported by grants by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, 14/2687-0, 18/14267-2, 18/02972-3) and Departamento de Ciencia e Tecnologia (DECIT), Ministry of Health, Brazil (PRONON, SIPAR 2500.035-167/2015-23).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the ethics committee of the A.C.Camargo Cancer Center (protocol 2134/15). Written and informed consents were obtained from all subjects or their guardians.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are contained in the manuscript and in its supplementary information files
